CGEN - Compugen Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.1700
+0.1300 (+3.22%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.0400
Open4.1000
Bid3.6500 x 900
Ask4.7700 x 1300
Day's Range4.0560 - 4.2200
52 Week Range2.0000 - 4.5000
Volume64,336
Avg. Volume205,478
Market Cap263.554M
Beta (3Y Monthly)2.76
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • PR Newswire

    Compugen to Present Data from Ongoing COM701 Phase 1 Clinical Trial at SITC 2019

    HOLON, Israel, Oct. 2, 2019 /PRNewswire/ -- October 2, 2019 – Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced it will present three posters at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019) to be held November 6-10 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland.

  • PR Newswire

    Compugen Presents Update on COM701 Phase 1 Study at 2019 IGCS

    In a poster titled "COM701 (A Novel Immune Checkpoint Inhibitor) in Patients with Advanced Solid Tumors," the Company reported that it has completed enrollment in the seventh dose level in the COM701 monotherapy (Arm A) and second dose level in the combination of COM701 with Opdivo® (Nivolumab) (Arm B) and that no dose-limiting toxicities were observed in these and prior dose level cohorts. COM701 as a monotherapy and in combination with Opdivo has shown an acceptable safety and tolerability profile at all dose levels tested.

  • PR Newswire

    Compugen Reports Second Quarter 2019 Results

    HOLON, Israel , Aug. 5, 2019 /PRNewswire/ -- Compugen Ltd.  ( Nasdaq: CGEN ), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today reported financial ...

  • PR Newswire

    Compugen Second Quarter 2019 Conference Call Scheduled for Monday, August 5, 2019 at 8:30 AM ET

    HOLON, ISRAEL , July 22, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN ), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that ...

  • PR Newswire

    Compugen Expands Intellectual Property Portfolio for COM701 with New U.S. Patent Covering Combination Use with anti-PD-1 Antibody

    Previously granted U.S. Patent protects combination of COM701 and COM902 HOLON, Israel , July 16, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader ...

  • PR Newswire

    Compugen Appoints Eran Perry to Its Board of Directors

    HOLON, Israel, July 2, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced the appointment of Mr. Eran Perry to its board of directors, effective July 1, 2019. In addition, the Company announced that Yair Aharonowitz, Ph.D. and Arie Ovadia, Ph.D. will retire from its board of directors and will not be brought for re-election at the next annual general meeting. "Eran is an accomplished business leader with over 20 years of experience in the healthcare industry as well as general management, strategy and finance.

  • PR Newswire

    Compugen Presents Update on COM701 Phase 1 Trial at the 2019 ASCO Annual Meeting

    HOLON, Israel, June 3, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, was featured in a trial-in-progress poster at the 2019 ASCO Annual Meeting in Chicago, IL. In a poster (Abstract #TPS2657), titled "A phase I study evaluating COM701 in patients with advanced solid tumors," the Company reported that the sixth patient dose cohort of COM701 monotherapy has been completed and that no dose-limiting toxicities were observed in this and prior dose cohorts. The poster is available on Compugen's website at www.cgen.com.

  • PR Newswire

    Compugen to Present at the Jefferies 2019 Healthcare Conference

    HOLON, Israel , May 22, 2019 /PRNewswire/ -- Compugen Ltd.  (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that ...

  • PR Newswire

    Compugen Reports First Quarter 2019 Results

    HOLON, Israel , May 20, 2019 /PRNewswire/ -- Compugen Ltd.  (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today reported financial ...

  • PR Newswire

    Compugen Doses First Patient in COM701/Opdivo® (Nivolumab) Combination Arm of Phase 1 Study in Patients With Advanced Solid Tumors

    HOLON, Israel, May 20, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that it has dosed the first patient in the combination arm of its Phase 1 study, combining escalating doses of COM701 with a fixed dose of Opdivo® (nivolumab) in patients with advanced solid tumors. "Our successful progression through the COM701 monotherapy dose escalation arm, enabled us to initiate the combination study with COM701 and Opdivo," stated Anat Cohen-Dayag, Ph.D., President and CEO of Compugen.

  • PR Newswire

    Compugen First Quarter 2019 Conference Call Scheduled for Monday, May 20, 2019 at 8:30 AM ET

    HOLON, Israel , May 6, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that ...

  • PR Newswire

    Compugen Presents Update on COM701 Phase 1 Trial at the 2019 AACR Annual Meeting

    HOLON, Israel, April 3, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, was featured in a trial-in-progress poster at The 2019 AACR Annual Meeting in Atlanta, GA. In a poster titled "Phase I study of COM701 (a novel checkpoint inhibitor of PVRIG) in patients with advanced solid tumors", the Company reported that the fifth dose level patient cohort of COM701 monotherapy has been completed and that no dose-limiting toxicities were reported. The poster presented at the meeting is available on Compugen's website.

  • PR Newswire

    Chinese Regulatory Authority Approves IND Application of Oramed's Oral Insulin Capsules

    NEW YORK, March 26, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Chinese partner, Hefei Tianhui Incubator of Technologies Co., Ltd. ("HTIT"), has reached the significant regulatory milestone of approval of an investigational new drug application ("IND") for two doses of its oral insulin (ORMD-0801).  The approval of the IND by the Center For Drug Evaluation of the China National Medical Products Administration ("NMPA", formerly the CFDA) of the oral insulin paves the way for the start of clinical trials in China. "We are pleased that the Chinese regulatory authorities have approved the IND, as it sets a clear path forward for approval of oral insulin in China, bringing oral insulin closer to becoming a reality in the Chinese market," stated Oramed CEO Nadav Kidron.

  • PR Newswire

    Compugen Announces Purchase of Company Shares by its Board of Directors and Members of Management

    "My fellow board members and I are excited about Compugen's unique value proposition, its proven computational discovery platform, and differentiated therapeutic pipeline that is designed to address significant unmet needs in immuno-oncology," said Paul Sekhri, Chairman of the Board. "We have the highest confidence in this management team and employees whose talent and dedication made possible the acomplishments of 2018, including the intiation of two clinical trials as well as partnerships with Bristol-Myers Squibb and AstraZeneca.

  • PR Newswire

    Compugen Announces Issuance of Two U.S. Composition of Matter Patents for COM701, Its Lead Immuno-Oncology Product Candidate

    HOLON, Israel, March 12, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that the United States Patent and Trademark Office (USPTO) has granted two composition of matter patents for COM701, the Company's lead immuno-oncology therapeutic antibody candidate. The composition of matter patents expand Compugen's intellectual property protection for COM701 beyond the therapeutic use patent received as part of the Moonshot program in 2017 and cover exclusivity on COM701 in the United States for any purpose.

  • PR Newswire

    Compugen to Present at the Cowen and Company 39th Annual Health Care Conference

    HOLON, Israel , March 5, 2019 /PRNewswire/ --  Compugen Ltd.  (NASDAQ: CGEN ), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced ...

  • PR Newswire

    Compugen Presents Update on COM701 Phase 1 Trial at ASCO-SITC Clinical Immuno-Oncology Symposium

    HOLON, Israel, March 1, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, was featured in a trial-in-progress at The ASCO-SITC Clinical Immuno-Oncology Symposium.  In poster titled "A Phase 1 Study Evaluating COM701 in Patients With Advanced Solid Tumors," the Company reported that the third single subject dose cohort has been completed with no dose-limiting toxicities (DLTs) reported. "We continue to see significant interest in the study from investigators as they recognize the potential and differentiation of COM701 relative to other checkpoint inhibitors in development," said Henry Adewoye, M.D., Chief Medical Officer at Compugen.

  • PR Newswire

    Compugen Reports Fourth Quarter and Full Year 2018 Results and Announces Corporate Restructuring to Streamline Operations

    Anticipated cost reductions expected to extend cash runway to allow the planned expansion of the ongoing COM701 Phase 1 study Company remains committed to investing in proprietary computational discovery ...

  • PR Newswire

    Compugen Fourth Quarter and Full Year 2018 Conference Call Scheduled for Tuesday, February 26, 2019 at 8:30 AM ET

    HOLON, Israel , Feb. 14, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will ...

  • PR Newswire

    Compugen Announces Publication of Two Peer-Reviewed Papers Demonstrating the Role of PVRIG as a Novel Immune Checkpoint for Cancer Immunotherapy

    HOLON, Israel, Jan. 22, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced the online publication of preclinical data demonstrating the role of PVRIG as a novel immune checkpoint and the potential of COM701, Compugen's first-in-class inhibitory antibody targeting PVRIG, to serve as an effective cancer immunotherapy. The findings were published in two peer-reviewed papers in Cancer Immunology Research, an American Association for Cancer Research publication. Both papers were co-authored by Compugen's scientists in collaboration with scientists from Johns Hopkins University School of Medicine, headed by Drew Pardoll, M.D., Ph.D., Abeloff Professor of Oncology, Medicine, Pathology, and Molecular Biology and Genetics at Johns Hopkins University, School of Medicine, and Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy and Co-Director of the Cancer Immunology Program at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, and Chairman of Compugen's Scientific Advisory Board.

  • PR Newswire

    Compugen's Phase 1 Trial of COM701 Featured as a Trial-in-Progress at The ASCO-SITC Clinical Immuno-Oncology Symposium

    HOLON, Israel, Jan. 14, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, will be featured in a trial-in-progress poster at The ASCO-SITC Clinical Immuno-Oncology Symposium, taking place February 28-March 2, 2019, in San Francisco, CA. Compugen is a clinical-stage, therapeutic discovery and development company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class therapeutics in the field of cancer immunotherapy.

  • GlobeNewswire

    New Research Coverage Highlights Vulcan Materials, Cimpress N.V, Asterias Biotherapeutics, ElectraMeccanica Vehicles, Compugen, and China HGS Real Estate — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • PR Newswire

    Compugen Announces Issuance of U.S. Patent for COM902, Its TIGIT Antibody Product Candidate for Cancer Immunotherapy

    HOLON, Israel, Nov. 13, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that a patent for COM902, the Company's TIGIT therapeutic antibody candidate, has been issued by the United States Patent and Trademark Office (USPTO) under the USPTO's Cancer Moonshot Pilot Program providing early examination of patent applications pertaining to cancer immunotherapy. Activating T cells results in stimulating the immune system, and therefore could be used for cancer immunotherapy treatment. This patent as well as other patents the Company is pursuing for COM902 are part of its global patent strategy covering its innovative immuno-oncology pipeline.

  • PR Newswire

    Compugen Reports Third Quarter 2018 Results

    HOLON, Israel , Nov. 7, 2018 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for ...

  • PR Newswire

    Compugen Third Quarter 2018 Conference Call Scheduled for Wednesday, November 7, 2018 at 8:30 AM ET

    HOLON, Israel , Oct. 24, 2018 /PRNewswire/ --  Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company ...